Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Let's take a look at what these Wall Street heavyweights have to say about CRISPR Therapeutics AG (CRSP) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
CRISPR Therapeutics currently has an average brokerage recommendation (ABR) of 1.88, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 27 brokerage firms. An ABR of 1.88 approximates between Strong Buy and Buy.
Of the 27 recommendations that derive the current ABR, 15 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 55.6% and 3.7% of all recommendations.
Check price target & stock forecast for CRISPR Therapeutics here>>>
The ABR suggests buying CRISPR Therapeutics, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Looking at the earnings estimate revisions for CRISPR Therapeutics, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at -$5.54.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for CRISPR Therapeutics. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for CRISPR Therapeutics.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
ExxonMobil Is One of the Largest Energy Companies by Market Cap. But Is It a Buy?
Over the last 12 months, ExxonMobil generated about $340 billion in revenue. ExxonMobil stock has significantly underperformed the S&P 500's total return over the last 10 years. 10 stocks we like better than ExxonMobil › ExxonMobil (NYSE: XOM) is one of the oldest and most iconic companies in American financial history. It's also gigantic. With a current market cap of nearly $500 billion, ExxonMobil is the 17th-largest American company overall, and the largest American energy company. But is ExxonMobil stock a good investment? Let's dig into the bull and bear cases. ExxonMobil bulls can point to several key points for why the stock is poised to deliver solid returns. First, ExxonMobil's global scale and diversification make it a solid choice for investors looking for an energy sector pick. The company has operations spread over dozens of countries, including Indonesia, Guyana, Papua New Guinea, Qatar, and, of course, the United States of America. In addition to this geographical diversification, the company enjoys diversification among its revenue streams. The company has upstream operations, focusing on exploring for and developing sources of energy. It also has downstream product divisions, which refine and sell fuel, lubricants, and other petrochemical products. What's more, ExxonMobil does this on a massive scale. Over the last 12 months, the company generated $340 billion in revenue. All of this makes ExxonMobil of central importance to the smooth running of the world economy. Turning more directly to its financials, the company has generated $33 billion in net income over the last 12 months and $28 billion in free cash flow. Those figures, in turn, help support the company's massive $20 billion annual share buyback program and annual dividend payments of roughly $17 billion. For bears, the energy sector itself presents a key risk. To start, commodity prices are famously volatile, leading to difficulty in balancing growth, costs, and investments. Similarly, geopolitical risks abound. ExxonMobil's global presence makes the company and its global assets vulnerable to war, political upheavals, and natural catastrophes. Furthermore, ExxonMobil faces an endless parade of regulatory and environmental hurdles that can send costs ballooning higher or halt production at any number of facilities. Finally, and perhaps most importantly, ExxonMobil's stock hasn't performed very well in recent years. Since 2015, shares have logged a total return of 100%. However, that pales in comparison to the S&P 500 index, which has generated a total return of more than 246%. ExxonMobil is one of America's most legendary companies. It has far-reaching operations and generates an astronomical amount of revenue each year. However, despite its advantages, ExxonMobil stock has underperformed the S&P 500 for years. It is susceptable to massive risks ranging from war to natural disasters. Furthermore, much of its stock's total return comes from its dividend payments. Currently, the stock pays a quarterly dividend of $0.99 per share, amounting to a dividend yield of 3.6%. Considering that ExxonMobil stock has generated a compound annual growth rate (CAGR) of about 7.2% over the last decade, that means that roughly half of the stock's return over the last 10 years has come from its dividend alone. So, while ExxonMobil stock might be tempting to income-seeking investors, others might want to look elsewhere. Before you buy stock in ExxonMobil, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and ExxonMobil wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Jake Lerch has positions in ExxonMobil. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. ExxonMobil Is One of the Largest Energy Companies by Market Cap. But Is It a Buy? was originally published by The Motley Fool
Yahoo
26 minutes ago
- Yahoo
Should You Buy Lucid Stock While It's Below $3?
The electric vehicle industry is facing significant headwinds right now. Lucid's vehicles are expensive, and leadership stability is a big question mark. It's best to take a wait-and-see approach to Lucid stock rather than buying. 10 stocks we like better than Lucid Group › The electric vehicle industry is enticing because, despite some setbacks, many countries and customers around the world are shifting their attention to EVs. The gains in EV adoption are often attributed to both consumer interest and government incentives that spur industry growth. The result is that in 2024, there were 1.3 million EVs sold, an increase of 7% compared to the previous year. Still, it's not all sunshine and rainbows in the EV industry. The high cost of electric vehicles and lagging EV infrastructure are cited by consumers as a significant barrier to buying an electric vehicle. Lucid (NASDAQ: LCID) knows the struggle of getting EVs off the ground in the U.S. just as well as anyone. After years of slower-than-expected production and several changes in leadership, Lucid stock has plummeted. Shares are down about 50% from their 52-week high, putting its share price under $3 right now. With the steep decline, is now a good time to buy Lucid stock at a discount? I think investors are better off waiting to see how things shake out for the company. Here's why it's better not to buy Lucid right now. Having a long-term perspective about the stocks you own is an important investment strategy, which is why it's troubling to see the U.S. backing away from some of its EV infrastructure investments and incentives. First, the Trump administration has thrown cold water on the idea of keeping tax incentives for buying electric vehicles. The incentives were worth up to $7,500 for new vehicles, and while Lucid didn't qualify for them -- its EVs are too expensive -- the incentives still acted as a catalyst to boost the broader EV industry. With those going away, there's less incentive for buyers to purchase EVs and less incentive for automakers to make bold transitions to electrified models. Additionally, the administration has walked back the government's previous commitment to invest billions of dollars in EV charging infrastructure. A legal battle over the funding is underway, but if the administration gets its way, states may not receive the $5 billion in funding to build EV chargers across the country. Broad EV market conditions matter to Lucid because it's still a fledgling EV brand. In order to succeed, Lucid and its peers need high demand for their vehicles and a larger EV charging infrastructure in place. Unfortunately, that now looks less likely over the next few years. Of course, not all of Lucid's problems stem from outside forces. One problem Lucid is currently facing is that its vehicles are just too dang expensive for many American buyers. That's not only hurting Lucid's ability to expand its customer base, but it's also hurting its ability to scale its manufacturing more efficiently. To make a profit in the auto industry, companies need to have economies of scale for their product lineups, sharing components across many vehicles. Lucid's cheapest Air sedan starts at nearly $70,000, and its Gravity SUV starts at about $80,000. The Gravity is still in low production, so any cost savings by sharing parts haven't had time to kick in yet. More importantly, the Air and Gravity starting prices are expensive by even EV standards. The average transaction price for an EV in the U.S. in May was about $57,700. That makes the cheapest Air model 21% above the average EV price, and the Gravity 39% more expensive than the average. Lucid is expected to launch its Earth EV, priced around $48,000, in 2027 or 2028. This will eventually help Lucid to achieve more efficient production costs and potentially widen its customer base, but how well the company will be able to deliver on this and when the Earth actually goes on sale are big unknowns. It was just four months ago that Peter Rawlinson stepped down from the CEO position at Lucid. The company's COO, Marc Winterhoff, is now the interim CEO as the board searches for a permanent leader. While it may have been the right move for Lucid to look for new leadership, the fact that the company is still in the process of finding a permanent replacement at such a difficult time for Lucid means investors should probably be cautious about jumping in with Lucid right now. Leadership change can be normal, but Lucid is currently on its third CEO -- two permanent and one interim -- since 2019. I'd like to see more stability in the C-suite before I feel comfortable that Lucid is on the right track and able to deliver on its EV ambitions. I'm rooting for Lucid just as I am for many EV companies, but that doesn't mean I'd feel comfortable buying its stock right now. For all the reasons above, I think it's best to take a wait-and-see approach with Lucid before buying shares. Before you buy stock in Lucid Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lucid Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Should You Buy Lucid Stock While It's Below $3? was originally published by The Motley Fool
Yahoo
30 minutes ago
- Yahoo
Is the Cryptocurrency Era About to Begin? Blockchain Expert Mr. Brijmohan Singh Explores the Future of Digital Finance
LONDON, UNITED KINGDOM / / June 29, 2025 / As we move deeper into 2025, it has become increasingly clear that the global financial system is undergoing a historic transformation. Cryptocurrencies once viewed as speculative assets are now emerging as credible instruments of value, trust, and financial access. The era of digital finance is not only beginning it's accelerating. The global cryptocurrency market capitalization reached $3.44 trillion in May 2025, marking a 5.2% increase since the beginning of the year. Bitcoin continues to lead as the dominant digital asset, but what's more significant is the growing participation across sectors from institutional investors to small-scale users in emerging economies. This growth is not just about asset prices. It reflects a broader shift toward decentralized financial infrastructure. More than 562 million people worldwide now use cryptocurrencies, a figure that has grown over 34% from 2024. Countries across Asia, Africa, and Latin America are leading adoption, often out of necessity rather than novelty. In many of these regions, digital currencies provide faster, cheaper, and more accessible alternatives to traditional banking. From my research and observations, the biggest hurdle now lies not in technology, but in regulation. Without clear rules, the industry remains vulnerable to misuse and misunderstanding. We must avoid a fragmented patchwork of rules that stifle innovation. Instead, I advocate for regulatory frameworks that are clean, simple, and technology-adaptive. This challenge is global. In many regions, lawmakers are still struggling to define what cryptocurrency is let alone how to govern it. But well-structured regulation can serve as a catalyst rather than a constraint. The purpose of policy should be to encourage innovation while ensuring consumer protection and financial stability. That balance is crucial. It is also essential that we shift public perception away from short-term speculation. The true power of blockchain lies in its utility: near-instant, peer-to-peer, borderless transactions. Today, aid organizations are using blockchain to deliver emergency funds across conflict zones in under three minutes. Entrepreneurs are using it to raise capital without relying on centralized financial systems. The technology is already making a real difference. Looking forward, blockchain investment is expected to reach $19 billion by the end of 2025, up from $12.4 billion in 2023. The market outlook remains strong, with projections estimating a total crypto market value of $5.43 trillion by 2029. These numbers reflect growing confidence and institutional integration but they also reflect the urgency of doing things right. The cryptocurrency era is not a trend it is a structural shift. We are witnessing the beginning of a more transparent, efficient, and inclusive financial world. But the path ahead demands informed leadership, responsible innovation, and global collaboration. The time to shape that future is now. Mr. Brijmohan Singh is a distinguished blockchain expert and financial investor with over a decade of hands-on experience in the digital finance sector. Since the early days of decentralized technology, he has been at the forefront of shaping the crypto and blockchain ecosystem, offering strategic insights and advisory to both emerging startups and established institutions. His deep understanding of blockchain's potential has positioned him as a trusted voice in bridging traditional finance with innovative, decentralized models. Throughout his career, Mr. Singh has played a key role in accelerating the adoption of digital assets by supporting multiple platforms in scaling their infrastructure, navigating regulatory frameworks, and unlocking the true value of blockchain utility. His mission is to help build a more transparent, efficient, and inclusive financial system by leveraging blockchain technology to its fullest. With a commitment to innovation and responsible growth, he continues to influence the next generation of global digital finance. Media Contact: Crypto whalesEmail: cryptowhales@ SOURCE: Crypto whales View the original press release on ACCESS Newswire
